BioSpace News Archive

Ceapro Inc.(TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its shares have received Depository Trust Company (“DTC”) full-service eligibility in the United States.

Candela Corporation, a leading global medical aesthetic device company, has entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of MT.DERM’s medical microneedling products.

Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for RUXIENCE™ (rituximab),1 a potential biosimilar to MabThera® (rituximab)

A positive opinion for the approval of the company’s single-dose oral cholera vaccine, Vaxchora ® (Cholera Vaccine, Live, Oral).

Ambra Health, makers of the leading cloud-based, medical image management suite, today announced its recognition as the 2020 KLAS Category Leader for Image Exchange.

PELITAS (“the Company”), a leading provider of healthcare Patient Access technology solutions, announced today that it has been recognized as 2020 Best in KLAS® for the Patient Access technology category.

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today that it has received a letter from The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Compensation Committee of the Board of Directors has approved an inducement award consisting of a stock option to purchase up to 156,000 shares of the Company’s common stock to David E. Strauss.

DarioHealth Corp. (Nasdaq: DRIO) (“DarioHealth” or the “Company”), a pioneer in the global digital therapeutics market, announced today that on January 30, 2020, Richard Anderson was granted a non-qualified stock option award to purchase 90,000 shares of the Company’s common stock, as well as an additional non-qualified performance-based stock option award to purchase an additional 90,000 shares of the Company’s common stock

MedPro Healthcare Staffing has received the healthcare staffing Gold Seal of Approval under The Joint Commission.